Cost-Effectiveness of Continuation Maintenance Pemetrexed After Cisplatin and Pemetrexed Chemotherapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: Estimates From the Perspective of the Chinese Health Care System

Clinical Therapeutics

Volumn 35, Issue 1, 2013, Pages 54-65

  Zeng, Xiaohui ^a,b   Peng, Liubao ^b   Li, Jianhe ^a,b   Chen, Gannong ^b   Tan, Chongqing ^a,b   Wang, Siying ^a,b   Wan, Xiaomin ^a,b   Ouyang, Lihui ^a,b   Zhao, Ziying ^a,b  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PEMETREXED; PLACEBO;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHINESE; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; LUNG NON SMALL CELL CANCER; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHINA; CISPLATIN; CLINICAL TRIALS, PHASE III AS TOPIC; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84872390640     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.12.013     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M.M., et al. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 2007, 57:43-66.
4. Non-small cell lung cancer (version 3.2012) Nation Comprehensive Cancer Network, Accessed September 24, 2012. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
5. Azzoli C.G., Baker S., Temin S., et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009, 27:6251-6266.
6. Scagliotti G.V., Parikh P., Von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
7. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
8. Scagliotti G., Hanna N., Fossella F., et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009, 14:253-263.
9. Ciuleanu T., Brodowicz T., Zielinski C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009, 374:1432-1440.
10. Paz-Ares L., De Marinis F., Dediu M., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncology 2012, 13:247-255.
11. Brodowicz T., Krzakowski M., Zwitter M., et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial. Lung Cancer 2006, 52:155-163.
12. Fidias P.M., Dakhil S.R., Lyss A.P., et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009, 27:591-598.
13. Greenhalgh J., McLeod C., Bagust A., et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010, 14:33-39.
14. Klein R., Wielage R., Muehlenbein C., et al. Cost-effectiveness of pemetrexed as first-line maintenance therapy for advanced nonsquamous non-small cell lung cancer. J Thor Oncol 2010, 5:1263-1272.
15. Tsuchiya T., Fukuda T., Furuiye M., et al. Pharmacoeconomic analysis of consolidation therapy with pemetrexed after first-line chemotherapy for non-small cell lung cancer. Lung Cancer 2011, 74:521-529.
16. Matter-Walstra K., Joerger M., Kühnel U., et al. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system. Value Health 2012, 15:65-71.
17. Wu B., Ye M., Chen H., et al. Costs of trastuzumab in combination with chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer: an economic evaluation in the Chinese context. Clin Ther 2012, 34:468-479.
18. Wu B., Dong B., Xu Y., et al. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One 2012, 7:e32530.
19. Wu B., Chen H., Shen J., et al. Cost-effectiveness of adding Rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China. Clin Ther 2011, 33:1446-1455.
20. Market study reports of anticancer drugs (2010) Guangzhou Pharmaceuticals Corporation of Punctuation Information, [in Chinese], Accessed September 24, 2012. http://www.menet.com.cn/.
21. National Development and Reform Commission, Accessed September 24, 2012. http://en.ndrc.gov.cn/.
22. The Publicity Medicine Prices of Hunan [in Chinese] Accessed September 24, 2012. http://www.hnyyjg.com/.
23. Carlson J., Garrison L., Ramsey S., et al. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health 2009, 12:20-27.
24. China Guidelines for Pharmacoeconomic Evaluations (Version 8) [in Chinese] China Center for Health Economic Research, Accessed September 24, 2012. http://www1.gsm.pku.edu.cn/article/143/8010.html.
25. Babar Z.U., Scahill S. Is there a role for pharmacoeconomics in developing countries?. Pharmacoeconomics 2010, 28:1069-1074.
26. Cleemput I., Neyt M., Thiry N., et al. Using threshold values for cost per quality-adjusted life-year gained in healthcare decisions. Int J Technol Assess Health Care 2011, 27:71-76.
27. National Bureau of Statistics of China, Accessed September 24, 2012. http://www.stats.gov.cn/english/.
28. Lee S.G., Jee Y.G., Chung H.C., et al. Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluororacil, doxorubicin and cyclophosphamide (FAC). Breast Cancer Res Treat 2009, 114:589-595.
29. Liubao P., Xiaomin W., Chongqing T., et al. Cost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamide. Pharmacoeconomics 2009, 27:873-886.